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Epidemiology
The colon and rectum comprise the final portion of the human
digestive tract, commencing at the ileocecal valve that marks
the end of the small intestine, terminating at the anus, and mea-
suring roughly one yard in length. Cancers of the colon and rec-
tum are the second leading cause of cancer incidence and can-
cer death among adult Americans, with 135,000 new cases and
57,000 deaths in 2001, and with a 6% lifetime risk of developing
the disease (Greenlee et al., 2001). Encouraging declines in the
death rate from colorectal cancer in the last decade speak to
the potential effectiveness of recent advances in prevention,
screening, and therapy. Cancers of the colon arise from the
colonic epithelial cells that line the lumen of the organ (Figure
1), which renew themselves every five days from a stem cell
population located at the base of colonic epithelial cell crypts.
Colon cancers are the end result of a multistep process of colon
neoplasia that extends over several years (Figure 2). First, neo-
plastic tubular colon adenomas arise as pedunculated polypoid
structures growing into the colon lumen. With time, they acquire
increasingly disordered villous histology and dysplastic cellular
cytology, and are recognized as frank cancers only when inva-
sive cells breach the underlying epithelial basement membrane
(Figure 1). Reproducible increases in incidence of the disease
in populations that have migrated from low to high incidence
regions of the world show the importance of environmental fac-
tors (Skibber et al., 2001). Cohort studies have rejected varia-
tions in intake of fiber, vegetables, and antioxidant vitamins as
causative factors, but support that risk increases with red meat
consumption, low folate intake, and sedentary lifestyle (Willett,
2001). The importance of genetic factors is shown by findings
that germline mutations in key colon cancer genes give rise to
familial hereditary colon cancer syndromes that account for
3%–7% of all cases annually (Kinzler and Vogelstein, 1996;
Skibber et al., 2001). Genetic susceptibility factors also likely
play a role in typical “sporadic” colon cancers, as indicated by
the 2- to 3-fold increased risk of colon cancers in first degree
relatives of persons affected by either colon cancer or by colon
adenomas developing before age 60 (Skibber et al., 2001).
Screening
In concept, most colon cancers could be prevented by detection
and removal of premalignant colon adenomas. Likewise, con-
siderable benefit would be predicted by detecting colon cancers
at early stages when the disease is amenable to cure by surgi-
cal excision. These considerations have lead to recommenda-
tions for mass screening starting at age 50 for the average risk
adult population, and earlier for individuals at higher risk due to
family history or other predisposing factors (Schoen, 2002;
Smith et al., 2001). Available screening modalities include
chemical testing for the presence of occult blood in the stool,
endoscopic visualization of the lower portion of the colon by sig-
moidoscopy, or full endoscopic visualization of the colon by
colonoscopy, with sensitivities for detecting cancer of
15%–30%, 60%, and 90%, respectively (Schoen, 2002; Smith
et al., 2001). The adoption of mass colonoscopic screening has
been impeded by the expense of the procedure and the 24 hr
required to undergo both a pretest laxative preparation and a
posttest recovery from sedation. The recent successful detec-
tion of colon cancer-specific mutations in DNA from the feces of
colon cancer patients has spurred considerable hope for the
development of molecularly based screening (Ahlquist and
Shuber, 2002; Traverso et al., 2002).
Staging, standard therapy, and outcomes
Colon and rectal cancers identified at early stages are highly
treatable and often cured with standard therapies. Surgical
resection of the involved colon is the initial treatment for colon
and many rectal cancers. The likelihood of a recurrence is relat-
ed to the degree of penetration of the tumor through the bowel
wall and the presence or absence of nodal involvement (Skibber
et al., 2001). These characteristics are the basis for the TNM
clinical staging system shown in Figure 2 and guide recommen-
dations for additional therapy.
Surgical resection is highly effective for early stage colon
cancers, providing cure rates of over 90% in stage I and 75% in
stage II disease. The presence of nodal involvement (stage III)
predicts for a 60% likelihood for recurrence (Skibber et al.,
2001). Treatment of these high-risk individuals with a postsurgi-
cal course of 5-Fluorouracil-based chemotherapy reduces the
recurrence rate to 40%, increasing overall survival to 60%, and
is now the standard of care for stage III patients (Skibber et al.,
2001); however, newer adjuvant regimens are clearly needed to
reduce the still substantial failure rate. The benefit of
chemotherapy in stage II patients, who already have a good
prognosis, has been harder to detect and remains controversial.
There is certainly a need to identify better prognostic factors
than TNM stage for guiding selection of individuals who will or
will not benefit from adjuvant therapy. Initial reports suggest that
good molecular prognostic markers (detailed below) include
findings of microsatellite instability and TGF-β receptor II muta-
tions (Watanabe et al., 2001), whereas adverse prognostic
markers include allelic losses on chromosomes 8p and 18q
(Zhou et al., 2002).
The management of rectal cancers is influenced by their
having an increased risk of local recurrence and by the desire to
maintain rectal sphincter function.The addition of radiation ther-
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apy either before or after surgery decreases local recurrence,
and the combination of chemotherapy and radiation therapy
with surgical resection is the standard treatment for stage II and
stage III rectal cancers (Skibber et al., 2001).
Metastatic colorectal cancer is present in 20% of individuals
at the time of initial diagnosis and develops within five years in
approximately 30% of those with initially localized disease. The
liver and lung are the common sites for metastasis, along with
peritoneal and local bowel recurrences. A small fraction of
metastases are localized and can be surgically removed with a
30% cure rate (Skibber et al., 2001). When surgery is not feasi-
ble, treatment with 5-fluouracil-based systemic chemotherapy
can have a palliative benefit with a modest increase in survival
and quality of life, but most patients succumb to the metastatic
disease within 2 years. Recently, several newer chemotherapies
have been shown to provide an average improved survival of
several months, including the topoisomerase I inhibitor irinote-
can (Saltz et al., 2000) and the DNA adduct forming agent oxali-
platin. The major impact of these agents is likely to be as part of
adjuvant therapies that are currently undergoing testing in clini-
cal trials for high-risk patients following surgery.
Hereditary colon cancer
Germline mutations in the APC gene cause the inherited famil-
ial adenomatous polyposis (FAP) syndrome, in which hundreds
to thousands of colonic adenomas develop during the third to
fourth decade of life, and the lifetime risk of colon cancer
approaches 100% (Goss and Groden, 2000; Kinzler and
Vogelstein, 1996). APC is a classic tumor suppressor gene, with
FAP tumors showing inactivation of the wild-type germline
allele, most often by deletion (Goss and Groden, 2000; Kinzler
and Vogelstein, 1996). APC protein functions as a suppressor of
Wnt signaling by catalyzing the degradation of β-catenin, and
thereby suppressing β-catenin mediated transcriptional activity
(Goss and Groden, 2000; Kinzler and Vogelstein, 1996). The
overwhelming majority of FAP associated APC mutations are
nonsense mutations that truncate the APC protein amino termi-
nal to the β-catenin interacting domain. Mutations at either the
extreme 5′ or 3′ of the APC locus result in an attenuated polypo-
sis phenotype. Intriguingly, adenomas in attenuated FAP often
reveal somatic mutations targeting both the germline mutant as
well as wild-type alleles (Goss and Groden, 2000; Kinzler and
Vogelstein, 1996). Moreover, germline APC alleles with subtle
50% underexpression can also cause the full FAP phenotype
(Yan et al., 2002). Lastly, an APC polymorphism (I1307K), rec-
ognized among the Ashkenazi Jewish population, creates a
DNA sequence hotspot for subsequent somatic mutation, and
this “premutation” increases colon cancer susceptibility approx-
imately 2-fold (Fearon and Gruber, 2001).
Germline mutations in components of the DNA Mismatch
Repair (MMR) complex are the genetic basis of hereditary non-
polyposis colon cancer (HNPCC) (Kinzler and Vogelstein, 1996;
Kolodner, 1996; Markowitz, 2000). Carriers of these autosomal
dominant mutations have an 80% lifetime risk of colon cancer,
most often localized to the ascending colon, and an increased
risk of gastric and endometrial cancers. Recent advances in
“conversion” technology allow sequencing of individual
germline alleles and show that over 90% of cases of classic
HNPCC arise from mutations in hMSH2 and hMLH1, which
encode two required components of the mismatch repair com-
plex (Yan et al., 2000). Moreover, germline mutations in hMSH6,
which encodes a component present in a subset of repair com-
plexes, have been associated with colon cancers with later age
of onset and less striking familial aggregation than classic
HNPCC (Kolodner et al., 1999). HNPCC tumors show somatic
inactivation of the second germline MMR allele. MMR inactiva-
tion induces a nearly 1000-fold increased spontaneous gene
mutation rates (Eshleman et al., 1995). This “mutator” pheno-
type accelerates the time for colon cancer development to less
than 36 months. This reflects in part the creation of mutational
hotspots within homopolymeric sequence repeats that are pre-
sent in the coding regions of some tumor suppressor genes.
The prototypical example is the biallelic mutational inactivation
of the type II TGF-β receptor, discussed below (Markowitz,
2000; Markowitz et al., 1995). Moreover, MMR deficient tumors
also accumulate frameshift mutations in over 40% of noncoding
repetitive microsatellite alleles, and such “microsatellite instabil-
ity” (MSI) is virtually diagnostic of MMR deficient cancers
(Boland et al., 1998).
Somatic genetics of colon cancer
Genetic instability is a necessary molecular catalyst for colon
carcinogenesis. Mismatch repair gene inactivation underlies
genomic instability in the 13% of colon cancers with the MSI
phenotype (Kinzler and Vogelstein, 1996; Markowitz, 2000).
These sporadic MSI tumors are nearly always near diploid
(Lengauer and Vogelstein, 1998). In contrast, chromosomal
instability is demonstrated by microsatellite stable tumors that
Figure 1. Clinical staging of colon cancer relative
to the histology of the normal colon 
Clinical staging of colon cancer relative to the
histology of the normal colon. Shown are the
principle layers of the colon including the
mucosa (1), the submucosa (2), the muscle of
the muscularis propria (3), and the subserosa (4).
Also shown are micrographs of a lymph node in
the colonic mesentery, and of the distant liver.
The outlines show the extent of spread of differ-
ent potential tumors and their stages as defined
by the commonly employed TNM (tumor, nodes,
metastasis) staging system. T1N0M0 (stage I)
cancers are confined to the submucosa.
T2N0M0 (also stage I) cancers invade the major
muscular layer (muscularis propria). T3N0M0
(stage II) cancers breach the muscular layer.
Cancers metastatic to mesenteric lymph nodes
(N13) are designated stage III. Cancers
metastatic to distant organ sites (M1) such as the
liver are designated stage IV.
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frequently show both chromosomal rearrangements and aneu-
ploidies (Lengauer and Vogelstein, 1998). While rare mutations
have been detected in BUB family genes that encode compo-
nents of the mitotic spindle, the common basis of chromosomal
instability remains unknown (Lengauer and Vogelstein, 1998).
MSI cancers largely arise in the right colon, most frequently
in persons not belonging to HNPCC kindreds. The most com-
mon cause of these sporadic MSI tumors is epigenetic methyla-
tion affecting both hMLH1 alleles (Markowitz, 2000). Such epi-
genetic methylation can serve as a tumor marker and has, for
example, been detected preoperatively in blood from MSI colon
cancer patients (Grady et al., 2001). Moreover, a propensity to
aberrantly methylate multiple genomic loci may define a distinct
class of colon cancers (dubbed CIMP) (Toyota et al., 1999).
Confirming this model, and elucidating new genetic targets of
aberrant methylation, are issues of great currency (Moinova et
al., 2002).
Activation of the Wnt signaling pathway is an early event
required for colon adenoma formation, and greater than 70% of
nonfamilial colon cancers bear somatic APC mutations.
Alternatively, some colon cancers activate Wnt signaling via acti-
vating mutations of β-catenin. Genes induced by Wnt activation
include c-myc, cyclin D1, and PPAR-δ (Goss and Groden, 2000).
RAS mutations, mainly in K-ras, develop in 50% of large
adenomas and 50% of colon cancers, and so are early steps in
neoplastic progression (Fearon and Gruber, 2001).
Mutations inactivating the TGF-β receptor II (TGFβ-RII)
gene arise in 30% of colon cancers and are temporally coinci-
dent with the further progression of colon adenomas to colon
carcinomas (Markowitz, 2000; Markowitz et al., 1995). MSI can-
cers ubiquitously inactivate TGFβ-RII by frameshift mutations
within a 10 base pair coding region poly-adenine repeat
(Markowitz, 2000; Markowitz et al., 1995). In microsatellite sta-
ble colon cancers, TGF-β signaling is inactivated by somatic
mutations in the TGFβ-RII kinase domain (15% of cases) or in
SMAD4 (15% of cases) or SMAD2 (5% of cases) transcription
factors that are phosphorylated by the TGF-β receptor complex
(Markowitz, 2000).
Mutational inactivation of p53 is also coincident with pro-
gression of colon adenomas to carcinomas. Greater than 50%
of colon cancers bear p53 mutations, and these mutations, first
discovered in human colon cancers, are now recognized as the
most common genetic event in human cancer (Fearon and
Gruber, 2001).
Most recently, overexpression of the PRL-3 tyrosine phos-
phatase has been observed in metastatic colon cancers, and
shown to be due to 25-fold gene amplification in 25% of cases,
suggesting that PRL-3 is a direct genetic target contributing to
metastatic progression (Saha et al., 2001).
Lastly, loss of Muc2 mucin expression, a frequent event in
human colon adenomas and cancers, induces intestinal can-
cers in Muc2 knockout mice (Velcich et al., 2002).
Growth factor pathways are drug targets in colon cancer
Colon adenomas and colon cancers show increased levels of
COX2 (Stack and DuBois, 2001), which with COX1 encodes
enzymes that initiate the synthesis of prostaglandins and other
eicosnoids. COX2 knockout mice demonstrate remarkable
resistance to intestinal adenoma formation (Oshima et al.,
1996), and nonsteroidal antiinflammatory drugs that inhibit
COX2 induced shrinkage of some colon adenomas in human
clinical trials (Stack and DuBois, 2001). Chronic use of COX2
inhibiting drugs, including aspirin, is associated with a
decreased risk of human colon cancer, and the potential of
these drugs for preventing colon adenomas and cancers is cur-
rently being evaluated in prospective clinical trials.
Studies in cell line and xenograft models suggest that
autocrine activation of EGF-R and ErbB2, which are not ampli-
fied in colon cancer, is nonetheless requisite for growth of these
cancer cells (Jiang et al., 1998), and is hence a target for anti-
cancer therapeutics (Mendelsohn and Baselga, 2000).
Pharmacologic or genetic inhibition of EGF-R activity impedes
growth of human colon adenomas in culture and development
of intestinal adenomas in murine models (Roberts et al., 2002;
Torrance et al., 2000). Combining an anti-EGF-R monoclonal
antibody, C225, with a cytotoxic agent, Irinotecan, gave signifi-
cant antitumor effect in patients whose cancer was not respond-
ing to Irinotecan alone, implying that interruption of the EGFR
signaling reversed resistance to Irinotecan (Saltz et al., 2001).
While these initial studies need confirmation, they suggest that
interruption of a growth factor signaling pathway overcomes
resistance to a cytotoxic drug. Small molecules showing
promise in preclinical models include inhibitors of EGF-R
(Mendelsohn and Baselga, 2000), downstream inhibitors of the
mitogen-activated protein (MAP) kinase pathway, and a
rapamycin analog that targets TOR. However, disabling a single
molecular target may not always give dramatic clinical effects,
as shown by the lack of activity in the clinic of initially promising
inhibitors of RAS oncogenes and of tumor angiogenesis.
Challenges
Colon cancer stands as a paradigm for our understanding of the
molecular basis of human cancer. Much work remains to be
done in discovering genes that contribute to such basic disease
phenotypes as chromosomal instability and metastatic spread,
and in translating the advances in understanding the molecular
Figure 2. Colon cancer progression 
Hematoxylin and eosin-stained sections show the progressive stages of
colon neoplasia. A: normal colonic mucosa; B: tubular adenoma; C: villous
adenoma; D: adenocarcinoma primary tumor; E: metastatic colon cancer
to the liver. Shown above each stage are associated changes in tumor
suppressor genes (designated by red lettering and red brakes) and onco-
genes (designated by green lettering and green arrows). Mismatch repair
gene inactivation is recognized by microsatellite instability and acts to
accelerate the progression pathway through increased gene mutation
rates. Shown below each stage are associated changes in growth factor
activities. Activation of COX2 and EGF-R contributes to initiation of colon
neoplasia, whereas TGF-β signaling suppresses neoplastic progression.
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biology of colon cancer into new clinical tools for prevention,
early diagnosis, and better treatments of this disease.
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